FIRST WAVE BIOPHARMA (FWBI) Stock Income Statement
USA - NASDAQ:FWBI - US33749P4081 - Common Stock
2.96 USD
+0.13 (+4.59%)
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 15.77M | 12.68M | 56.71M | 26.43M | 14.74M | |||
| Research and Development | 5.03M | 8.78M | 38.32M | 19.11M | 7.86M | |||
| Selling, General, and Administrative Expenses | 10.74M | 11.99M | 18.37M | 7.28M | 6.04M | |||
| Operating Income | -15.77M | -12.68M | -56.71M | -26.43M | -14.74M | |||
| Interest Income/Expense | -19.93K | -10.00K | -10.00K | -5.84M | -430.00K | |||
| Other Income/Expense | -4.22K | -1.94M | 530.00K | null | null | |||
| Non Recurring Items | null | 0 | -2.35M | -400.00K | null | |||
| Income Before Taxes | -15.79M | -14.63M | -58.54M | -32.67M | -15.18M | |||
| Income Tax | null | null | null | 0 | null | |||
| Net Income | -16.10M | -14.97M | -84.52M | -41.73M | -15.18M | |||
| EBITDA | -15.74M | -12.65M | -56.17M | -25.86M | -13.72M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -47.87719 | -20.79 | -2.11K | -4.17K | -1.52K | |||
| Non GAAP EPS | -88.75 | -362.3 | -1.25K | -255 | -218.53199999999998 | |||
| Statistics | ||||||||
All data in USD